EFFICACY OF SUBCUTANEOUS HOMOHARRINGTONINE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS (TKI) AND HARBORING A BCR-ABL MUTATION

被引：0
|
作者：
Marin, D. [1 ]
Maloisel, F. [3 ]
Legros, L. [2 ]
Nicolini, F. E. [4 ]
Roy, L. [5 ]
Rousselot, P. [6 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] CHU Hop Archet, Nice, France
[3] CHU Hosp Civil, Strasbourg, France
[4] CHU Hop Edouard Herriot, Lyon, France
[5] CHU Hop Jean Bernard, Poitiers, France
[6] Hop Andre Mignot, Le Chesnay, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O139
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
    Tikhonova, V.
    Misyurina, E.
    Kesaeva, L.
    Finashutina, Y.
    Krutov, A.
    Aksenova, E.
    Soldatova, I.
    Soldatkina, O.
    Ivanova, V.
    Novitskaya, N.
    Arshanskaya, E.
    Lazarev, I.
    Volkova, M.
    Pospelova, T.
    Konstantinova, T.
    Vysotskaya, L.
    Voloditcheva, E.
    Lapin, V.
    Davydkin, I.
    Turkina, A.
    Kolosheinova, T.
    Goryacheva, S.
    Chelysheva, E.
    Pristupa, A.
    Golubenko, R.
    Gavrilova, L.
    Volkova, S.
    Kuchma, G.
    Ovsyannikova, E.
    Zaklyakova, L.
    Kaplanov, K.
    Klitochenko, T.
    Misyurin, A.
    HAEMATOLOGICA, 2013, 98 : 548 - 548
  • [2] Stem Cell Transplant (SCT) for Patients (pts) with Chronic Myeloid Leukemia (CML) Resistant to Tyrosine Kinase Inhibitors (TKI) with BCR-ABL Kinase Domain (KD) Mutation T315I
    Velev, Nikolai
    Cortes, Jorge
    Champlin, Richard
    Kantarjian, Hagop M.
    Rondon, Gabriela
    Giralt, Sergio
    Borthakur, Gautam
    De Lima, Marcos
    BLOOD, 2008, 112 (11) : 738 - 738
  • [3] Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI).
    Jabbour, Elias
    Jones, Dan
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Wierda, William
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 225A - 225A
  • [4] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Hyewon Lee
    Igor Novitzky Basso
    Dennis Dong Hwan Kim
    International Journal of Hematology, 2021, 113 : 632 - 641
  • [5] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Lee, Hyewon
    Basso, Igor Novitzky
    Kim, Dennis Dong Hwan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
  • [6] THE ROLE OF STEM CELL TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT TO TYROSINE KINASE INHIBITORS WITH BCR-ABL KINASE DOMAIN MUTATION T315I
    Morozova, E.
    Vlasova, J.
    Afanasyev, B.
    HAEMATOLOGICA, 2015, 100 : 603 - 603
  • [7] Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study
    Iino, Masaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [9] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
    Gado, Sarah
    Hassan, Mohammed Al-Kassim
    Kisla, Mehmet Murat
    Ates-Alagoz, Zeynep
    MEDICINAL CHEMISTRY, 2024,
  • [10] Stem Cell Transplantation for Patients With Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors With BCR-ABL Kinase Domain Mutation T315I
    Velev, Nikolai
    Cortes, Jorge
    Champlin, Richard
    Jones, Dan
    Rondon, Gabriela
    Giralt, Sergio
    Borthakur, Gautam
    Kantarjian, Hagop M.
    De Lima, Marcos
    CANCER, 2010, 116 (15) : 3631 - 3637
12345